MapLight Therapeutics officer plans $563K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
MapLight Therapeutics, Inc. officer Christopher A. Kroeger reported a proposed sale of 20,822 common shares, with an aggregate market value of $562,610.44 and an approximate sale date of April 15, 2026. The shares are to be sold solely to satisfy tax-withholding obligations in connection with RSU vesting. The notice lists restricted stock unit grants of 14,844, 7,664 and 24,222 shares on July 30, 2023, November 9, 2023, and May 2, 2024, respectively.
Key Figures
Key Terms
Restricted Stock Unit Grant financial
RSU vesting financial
Aggregate Market Value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.